BBC Homepage World Service Education
BBC Homepagelow graphics version | feedback | help
BBC News Online
 You are in: Business
Front Page 
World 
UK 
UK Politics 
Business 
Market Data 
Economy 
Companies 
E-Commerce 
Your Money 
Business Basics 
Sci/Tech 
Health 
Education 
Entertainment 
Talking Point 
In Depth 
AudioVideo 

Wednesday, 15 November, 2000, 15:54 GMT
US approves Glaxo HIV drug
Worker at a GlaxoSmithKline factory in Germany
Trizivir should be in US shops next month
The UK drug giant Glaxo Wellcome has won accelerated approval from the US Food & Drug Administration for its new HIV treatment.

The company said the drug, called Trizivir, was the first medicine to contain three antiretrovirals in one tablet and should be available in US pharmacies in December.

"The benefits of Trizivir particularly relate to its potent HIV activity in antiretroviral naive patients and its convenient dosing regimen of only one tablet twice a day, with no food or water restrictions," Glaxo said in a statement.

Glaxo's shares improved modestly following the statement, standing 12 pence or 0.6% up on the day at 2040p by 1510 GMT.

'Positive opinion'

The company said Trizivir had already been approved in Mexico and had "received a positive opinion" from the EU's Committee for Proprietary Medicinal Products in July.

The drug's three active ingredients are abacavir sulphate, lamivudine and zidovudine.

Glaxo said combining the three substances in one tablet "should help people living with HIV to more easily incorporate medication into their daily routine".

The Trizivir treatment will complement a number of other Glaxo treatments for HIV - the virus that causes Aids.

Glaxo is currently merging with former UK rival SmithKline Beecham to create GlaxoSmithKline - the world's largest drug group by market share.

Search BBC News Online

Advanced search options
Launch console
BBC RADIO NEWS
BBC ONE TV NEWS
WORLD NEWS SUMMARY
PROGRAMMES GUIDE
See also:

01 Nov 00 | Health
Relenza 'could protect from flu'
31 Oct 00 | Business
Ribena slump confirms poor summer
26 Oct 00 | Health
Relenza: a drug too far?
11 Sep 00 | Business
Drug merger delay
27 Jul 00 | Business
Glaxo: More deals to come
Internet links:


The BBC is not responsible for the content of external internet sites

Links to more Business stories are at the foot of the page.


E-mail this story to a friend

Links to more Business stories